TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who participated in CQTI571A2301 clinical trial and completed the week 24 visit of the study protocol, including all Study Completion assessments~* Patients who withdrew from the CQTI571A2301 study prematurely for reasons not related to study drug or not related to a safety issue but performed all Study Completion assessments~Exclusion Criteria:~* Patients with a pulmonary capillary wedge pressure \> 15 mmHg at time of Study Completion assessments in core protocol CQTI571A2301. If pulmonary capillary wedge pressure is not attainable, then a left atrial pressure measurement may be used in its place.~* LVEF \< 45%~* Patients with thrombocytopenia, platelet count \< 50E9/L (50E3/µL)~* Patients with uncontrolled systemic arterial hypertension, systolic \> 160 mmHg or diastolic \> 90 mmHg~* Patients with a QTcF \> 450 ms for males and \> 470 ms for females in the absence of right branch bundle block (based on Visit 1 ECG if required to be performed)~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Core imatinib (Type: EXPERIMENTAL): Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
- Core placebo (Type: EXPERIMENTAL): Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Anidulafungin in Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥ 18 years) with a hematologic disorder AND an indication for IFI prophylaxis or therapy, but a relative contraindication for azoles or polyenes due to hepatic or renal dysfunction\*, are scheduled to receive anidulafungin for one of the following specific indications:~* Need for primary antifungal prophylaxis in patients with Acute leucaemia/MDS during induction, reinduction or consolidation chemotherapy (who are expected to become neutropenic for at least 10 days) OR after allogenic HSCT with GvHD (at least grade II or more - systemic steroid treatment required)~* Need for secondary antifungal prophylaxis in patients with the history of a proven or probable invasive fungal infection who are expected to become neutropenic during induction, reinduction or consolidation chemotherapy~* Indication for treatment of proven\*\*, probable or possible fungal infection:~  * Neutropenic patients with fever resistant to antibiotics (empirical use)~ * Neutropenic patients with fever resistant to antibiotics and additive laboratory or imaging signs of IFI (preemptive use)~ * Patients who failed other antifungal therapy due to intolerance or progressive infection~Exclusion Criteria:~* Absence of written informed consent~* Female patients who are pregnant or lactating~* Use of anidulafungin within 30 days prior to study~* Known hypersensitivity to anidulafungin~* Proven IFI with pathogen of known resistance to echinocandins (e.g. zygomycetes)~* Life expectancy less than 1 month~* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anidulafungin, safety, antifungal drug (Type: OTHER): single arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-65~* Meets DSM-IV criteria for major depressive disorder~* Meets eligibility criteria for clinical trial of ziprasidone augmentation of escitalopram~* Capable of providing informed consent~Exclusion Criteria:~* Meets exclusion criteria for augmentation clinical trial protocol~* Pregnancy or unwillingness to avoid pregnancy during trial~* Current or past psychosis or bipolar disorder~* Substance abuse or dependence in the past six months~* Clinically significant suicidality~* Unstable cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease or uncontrolled seizures~* Use of a concomitant medication that acts on glutamate or GABA neurotransmission~* Contraindication to magnetic resonance imaging (metal implant or device, occupational metal exposure, significant claustrophobia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- escitalopram responders no augmentation (Type: None): Participants who show a clinical response following 8 weeks on an SSRI will have a final magnetic resonance scan at the end of 8 weeks and will complete the study at that time.
- Ziprasidone augmentation (Type: None): Participants who do not respond to escitalopram and are randomized to ziprasidone augmentation will have a final magnetic resonance scan following 8 weeks on ziprasidone.
- Placebo augmentation (Type: None): Participants who do not respond to escitalopram and are randomized to placebo augmentation will have a final magnetic resonance scan following 8 weeks on placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MS patients with relapsing remitting MS/secondary progression MS (based on the 2010 revised McDonald criteria)~* Cognitive deficits~* Motor deficits~Exclusion Criteria:~* contraindication to tDCS (seizure or epilepsy, metal in the head, ...)~* major psychiatric conditions or major depression~* coexisting instable medical condition~* substance or alcohol abuse~* regular intake of drug that strongly modulate brain excitability~* major sequels from MS preventing participation in the study~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- real tDCS (Type: ACTIVE_COMPARATOR): Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks
- Sham tDCS (Type: PLACEBO_COMPARATOR): this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided PVB

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing programmed lateral or posterolateral thoracotomy, regardless of indication,~* Aged 18 to 80 years~Exclusion Criteria:~* Surgery performed in the emergency;~* Specific clinical contexts including neoplasia in terminal phase or palliative phase;~* Contraindications to the products of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ultrasoundguided paravertebral catheter (Type: EXPERIMENTAL): ultrasoundguided paravertebral catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* ≥ 18 years of age~* Medication refractory OAB, identified per American Urological Association guidelines~Exclusion criteria:~* Post void residual urine \>150ml on two occasions~* Untreated, symptomatic UTI~* Comorbid neurological conditions, including spinal cord injury, systemic neurologic illnesses (i.e. multiple sclerosis, Parkinson's disease) or central nervous system disease (i.e. brain tumor, stroke)~* Prior pelvic irradiation~* Current or prior bladder malignancy~* Hematuria lacking a clinically appropriate evaluation~* Chronic indwelling or intermittent catheterization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Periprocedural Antibiotics Only (Type: EXPERIMENTAL): Patients receive a one-time dose of antibiotics at the time of injection, prior to injection.
- Extended Antibiotics (Type: EXPERIMENTAL): Patients receive a peri-procedural dose of antibiotics and an extended (3-day) course of antibiotics to be taken post-procedurally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: POsitioning for Esophageal Cancer Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed, non-metastatic esophagus cancer (squamous or adenocarcinoma) or AEG I tumors requiring curative thoracoabdominal esophagectomy with intrathoracic anastomosis of a gastric tube immediately after diagnosis or after neoadjuvant treatment~* Patients are considered fit for surgery by a local interdisciplinary team of surgeons, medical oncologists and anesthesiologists (ECOG performance status of 0,1, or 2).~* Age ≥ 18 years~* Written informed consent~Exclusion Criteria:~* Preoperative established indication for colon interposition or cervical anastomosis~* Preoperative diagnosed tracheo-esophageal fistula~* History of right thoracotomy or prior lung surgery~* Physical inability of the described intraoperative patient positioning~* Non-malignant esophageal pathology or other malignancies except squamous or adenocarcinoma~* Planned laparoscopic or thoracoscopic surgical approach~* Patients not eligible for TAE (ASA ≥ 4)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Repositioning Group (Type: ACTIVE_COMPARATOR): The patient is placed on a vacuum mattress in supine position for the abdominal part using a midline laparotomy. After completion of the abdominal part, the abdomen is closed and dressed in standard fashion and the patient is repositioned under full anesthesia is a left-lateral decubitus (LLD) position. After the thorax is sterile prepped and draped, a right dorso-lateral thoracotomy in the 4th to 6th intercostal space under preservation of body of the serratus muscle is performed.
- Single positioning (Type: EXPERIMENTAL): The patient is placed on a vacuum mattress and in a left-screwed supine position for the entire operative procedure. The pelvis and the lower extremities are placed at 0° rotation, whereas the torso is rotated leftwards to an angle of 45° (Fig. 1). The patient is prepped and draped from the shoulders to the inguinal region. A midline laparotomy is done for the abdominal part and the abdomen closed afterwards. For the thoracic part, the operating table is tilted about 30° to the left, and a right anterolateral thoracotomy is performed in the 4th to 6th intercostal space.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intercostal Cryoneurolysis Following Traumatic Rib Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients of at least 18 years of age~* having 1-3 sustained rib fractures on either or both sides (if bilateral fractures, then total up to 6 fractures with up to 3 per side)~* regional anesthetic requested by the admitting service~* accepting of a cryoneurolysis procedure~Exclusion Criteria:~* chronic opioid use (daily use within the 2 weeks prior to surgery and duration of use \> 4 weeks~* pregnancy~* incarceration~* inability to communicate with the investigators~* morbid obesity (body mass index \> 40 kg/m2)~* possessing any contraindication specific to cryoneurolysis such as a localized infection at the treatment site, cryoglobulinemia, cold urticaria and Reynaud's Syndrome~* any patient unable to correctly perform incentive spirometry as this is an outcome measure~* any patient with any degree of decreased mental capacity as determined by the surgical service~* any reason an investigator believes study participation would not be in the best interest of the potential subject, including an anti-coagulated state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cryoneurolysis (active) (Type: EXPERIMENTAL): The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods.
- Sham (Type: SHAM_COMPARATOR): For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound for Double Lumen Endotracheal Tube

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Surgery requiring placement of double-lumen endotracheal tube.~* ASA 1-3~Exclusion Criteria:~* History of difficult or impossible intubation.~* Clinical findings of possible difficult intubation according to the standard preoperative airway assessment.~* Impossible placement of a double lumen tube

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ultrasound (Type: EXPERIMENTAL): Determination of correct placement of the double lumen tube by lung ultrasound.
- Clinical (Type: ACTIVE_COMPARATOR): Determination of correct placement of the double lumen tube by clinical examination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* G6PD deficiency by fluorescent Spot test (for intervention groups and control group receiving DHA-PPQ only (N=50)~* G6PD normal activity by fluorescent Spot test for control groups (N=20)~* Informed consent by participant or caregiver (an assent is required for those 12-17 years)~Exclusion Criteria:~* Enrolled in another clinical trial~* Fever: temperature \>37.5°C (axillary) or history of fever in the last 24 hours~* Evidence of severe illness or active infection other than malaria~* Known allergy to study medications~* Hb \<11 g/dL~* Antimalarials taken within the last 2 weeks~* PQ taken within the last 4 weeks and blood transfusion within the last 90 days~* Current use of tuberculosis or anti-retroviral medication, sulphonamides, dapsone, nitrofurantoin, nalidixic acid, ciprofloxacin, methylene blue, toluidine blue, phenazopyridine and co-trimoxazole.~* History of severe chronic illness

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- G6PD deficient 0.25 mg/kg PQ + DHAP (Type: EXPERIMENTAL): None
- G6PD deficient 0.4 mg/kg PQ + DHAP (Type: EXPERIMENTAL): None
- G6PD deficient DHAP only (Type: ACTIVE_COMPARATOR): None
- G6PD normal 0.25 mg/kg PQ + DHAP (Type: ACTIVE_COMPARATOR): None
- G6PD normal 0.4 mg/kg PQ + DHAP (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* o Age: 7 - 21 years old~  * Currently has a tracheostomy tube~ * One of previous 3 tracheostomy tube aspirate cultures positive for Pseudomonas aeruginosa~ * Non-smoker~ * Ability of parent to provide informed consent, as evidenced by signing a copy of the consent form approved by the Institutional Review Board of the subject's respective study institution.~ * Written assent for children 7-17 years of age.~ * Informed consent for children ages 18-21, as evidence by signing a copy of the consent form approved by the Institutional Review Board of the subject's respective study institution.~Exclusion Criteria:~* o History of immunodeficiency~  * History of cystic fibrosis. Primary ciliary dyskinesia, or bronchiectasis~ * History of tuberculosis~ * History of positive culture for Burkholderia cepacia~ * Use of inhaled antibiotics in the last 6 months

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): All participants will be receiving the study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Able and willing to give signed informed consent prior to enrollment~2. Male or female, ≥ 18 years of age~3. Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den Hoogen 2013): Score ≥ 9.~4. Patients with RHC data available from measurement within 3 weeks prior to TPD assessment~5. No change in or initiation of PAH specific therapy between the last RHC and TPD~Exclusion Criteria:~1. People unable or unwilling to give informed consent.~2. PCWP or LVEDP \> 15 mmHg~3. Any PH etiology outside Group 1 (Dana Point, 2008)~4. Pregnant women~5. Patients having severe chest wall deformity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doppler ultrasound (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues